Bb Biotech Ag Stock Current Valuation
| BBZA Stock | EUR 39.65 0.10 0.25% |
Valuation analysis of BB Biotech AG helps investors to measure BB Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that BB Biotech's price fluctuation is very steady at this time. Calculation of the real value of BB Biotech AG is based on 3 months time horizon. Increasing BB Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BBZA stock is determined by what a typical buyer is willing to pay for full or partial control of BB Biotech AG. Since BB Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BBZA Stock. However, BB Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.65 | Real 35.49 | Hype 39.65 | Naive 39.82 |
The real value of BBZA Stock, also known as its intrinsic value, is the underlying worth of BB Biotech AG Company, which is reflected in its stock price. It is based on BB Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BB Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BB Biotech AG helps investors to forecast how BBZA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BB Biotech more accurately as focusing exclusively on BB Biotech's fundamentals will not take into account other important factors: BB Biotech AG Company Current Valuation Analysis
BB Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BB Biotech Current Valuation | 226.69 M |
Most of BB Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BB Biotech AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BB Biotech AG has a Current Valuation of 226.69 M. This is 98.42% lower than that of the Healthcare sector and 95.12% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 98.64% higher than that of the company.
BBZA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BB Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BB Biotech could also be used in its relative valuation, which is a method of valuing BB Biotech by comparing valuation metrics of similar companies.BB Biotech is currently under evaluation in current valuation category among its peers.
BBZA Fundamentals
| Return On Equity | -0.12 | |||
| Return On Asset | -0.008 | |||
| Current Valuation | 226.69 M | |||
| Shares Outstanding | 54.85 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 7.93 % | |||
| Price To Earning | 4.19 X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 800,360 X | |||
| Revenue | (351.23 M) | |||
| Gross Profit | 4 K | |||
| Net Income | (357.81 M) | |||
| Book Value Per Share | 48.98 X | |||
| Cash Flow From Operations | (94.79 M) | |||
| Earnings Per Share | (6.58) X | |||
| Target Price | 59.87 | |||
| Number Of Employees | 10 | |||
| Beta | 0.87 | |||
| Market Capitalization | 2.98 B | |||
| Total Asset | 3.05 B | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 3.05 B | |||
| Last Dividend Paid | 2.85 |
About BB Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BB Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BB Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BB Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BBZA Stock
BB Biotech financial ratios help investors to determine whether BBZA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBZA with respect to the benefits of owning BB Biotech security.